NDAORALTABLETPriority Review
Approved
Apr 1967
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CHOLOXIN (dextrothyroxine sodium) is an oral tablet containing the dextro-isomer of thyroxine, approved in 1967 for lipid management. It functions as a thyroid hormone analog to reduce cholesterol levels in patients with hyperlipidemia. The drug represents a legacy small-molecule therapeutic from the pre-statin era.
LOE Approaching
Declining commercial relevance with approaching loss of exclusivity; team size and hiring activity likely minimal.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CHOLOXIN offers minimal career development opportunities given its approaching loss of exclusivity and marginal market position. Professionals assigned to this product face limited scope for strategic influence, team growth, or advancement in a competitive therapeutic category.
Brand Manager (legacy portfolio)Regulatory Affairs
Worked on CHOLOXIN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.